Veracyte Says At Least 18 Abstracts Focused On Decipher Prostate And Decipher Bladder Genomic Classifiers Will Be Presented At AUA 2025
Veracyte Says Data From Decipher Prostate Genomic Classifier Are Linked to Real-World Data in NCI's SEER Specialized Database Release
Express News | Veracyte Announces Decipher Prostate Genomic Classifier Results Are Linked to Real-World Data in National Cancer Institute’s Seer Specialized Database Release
Express News | Veracyte Inc : Leerink Partners Cuts Target Price to $45 From $50
Press Release: Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
Craig-Hallum Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $45
Craig-Hallum Reaffirms Their Buy Rating on Veracyte (VCYT)
Veracyte (VCYT) Just Overtook the 20-Day Moving Average
Are Veracyte, Inc.'s (NASDAQ:VCYT) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Guggenheim Maintains Veracyte(VCYT.US) With Buy Rating, Cuts Target Price to $37
Guggenheim Maintains Buy on Veracyte, Lowers Price Target to $37
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?
Veracyte Price Target Maintained With a $45.00/Share by Stephens & Co.
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's Is How to Trade
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests
Veracyte Announces New Data Showing That Its Whole-Genome Sequencing (Wgs)-Based Platform For Minimal Residual Disease Testing Detected Cancer In Patients Treated for Muscle-Invasive Bladder Cancer With More Accuracy Than Ddpcr-Based Blood Testing And...
Express News | Veracyte Inc - to Launch First Mrd Test for Mibc in H1 2026
Express News | New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based Mrd Testing Platform for Muscle-Invasive Bladder Cancer
Craig-Hallum Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $45
Veracyte Analyst Ratings